MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » TCT 2013: St. Jude Medical’s Portico valve looks good at 30 days

TCT 2013: St. Jude Medical’s Portico valve looks good at 30 days

By

TCT 2013: St. Jude Medical's Portico valve looks good in new sizes

Minnesota medical device maker St. Jude Medical (NYSE:STJ) this week released results from clinical trials of its 23 mm and 25 mm Portico transcatheter aortic valve implantation devices, touting patient health improvements and low adverse events at 30 days.

The Portico system aims to address challenges discovered with early generations of TAVI technology, including difficulty getting the cardiac implants positioned accurately, valve leakage and heart block development that requires permanent pacemaker implantation, among other issues. The device can be fully re-sheathed into its delivery catheter during the procedure, allowing a cardiologist to reposition the device or retrieve it entirely.

Lead investigator Dr. Ganesh Manoharan presented 1-month results from the Portico CE study of 84 patients, reporting a 3.6% mortality rate, 2.4% major stroke rate, 10.8% pacemaker implantation rate and 10.8% major bleeding rate, results that Manoharan referred to as "an excellent safety profile."

"St. Jude Medical has a long history of developing world class heart valve technologies. Today’s positive results speak to our capability and commitment to bring meaningful advancements to patients with heart valve disease," company cardiovascular & ablation technologies president Frank Callaghan said in prepared remarks.

The study was initiated to evaluate the 23 mm Portico valve, which last year won CE Mark approval in the European Union, and the trial was expanded to include the 25 mm valve, which is currently under regulatory review.

St. Jude is pretty far behind its rival medtech giants in terms of getting a TAVI device on the market, following Edwards Lifesciences’ (NYSE:EW) FDA-approved Sapien system and Medtronic’s (NYSE:MDT) CoreValve, which is slated to hit the U.S. market next year.

TAVI systems have gotten a lot of attention at this year’s TCT conference, where researchers discussed the cost-effectiveness of extending the procedure to lower-risk patients, Medtronic delved deeper into 1-year “real-world” clinical results for its CoreValve system, and researchers pitted CoreValve and Sapien against one another, finding few differences outside of a higher pacemaker implantation rate for CoreValve.

In case you missed it

RSS From Medical Design & Outsourcing

  • These medtech companies care a lot about research
    They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report… […]
  • Traco Power launches new AC/DC power supplies
    Traco Power (Baar, Switzerland) announced its newest high efficiency, miniaturized ac/dc power supplies: the TPP 180 series for medical and industrial and TPI 180 for industrial. The power supplies measure only 2-by-3-by-1.24 inches in the open frame version — with global safety approvals for medical or industrial markets. They come in16 standard models with single… […]
  • NIH launches $9.8M neuromodulation competition
    The National Institutes of Health (NIH) announced today that it launched the first phase of its Neuromod Prize competition. Neuromod Prize, a $9.8 million competition, aims to accelerate the development of neuromodulation therapies. NIH seeks scientists, engineers and clinicians to submit novel concepts and clinical development plans to demonstrate solutions for stimulating the peripheral nervous… […]
  • Junkosha boosts production of PTFE liners and FEP-based heat shrink
    Junkosha announced today that it plans to double production capacity to meet shortages of PTFE liners and FEP-based heat shrink for catheter manufacturers. Both OEMs and contract manufacturers in the catheter space are stressed from shortages in the global supply of vital components, according to the Japanese maker of sophisticated fluoropolymer application technologies. “We believe this… […]
  • Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022
    With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022. Across 2021, Dexcom (NSDQ:DXCM) took several steps forward. The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a major regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple. As the new year gets underway, expectations for the… […]
  • Former Zimmer Biomet executive has a new job
    Carrie Nichol, the former chief accounting officer of Zimmer Biomet (NYSE:ZBH), has a new job outside of the medtech industry. Nichol, who also served as vice president, controller and principal accounting officer at Zimmer Biomet, is now a VP and controller at Minnetonka, Minnesota-based Cargill. Her departure was among the many notable medtech executive moves… […]
  • Employees say Intuitive, Boston Scientific, J&J, Medtronic are among the best places to work in 2022
    Intuitive Surgical, Boston Scientific, Johnson & Johnson and Medtronic were recently named by Glassdoor as Best Places to Work in 2022 based on employee reviews. Each year, Glassdoor uses feedback that employees have shared on the website over the past 12 months to compile a list of the best places to work for the upcoming… […]
  • Medtronic’s M&A strategy explained by CFO Karen Parkhill
    When Medtronic CFO and EVP Karen Parkhill looks back at the medical device manufacturer’s performance through the COVID-19 pandemic, she recalls a key decision that rankled investors but paid off in the long run. “When I first joined Medtronic, it was shortly after the Covidien merger and we had taken on a lot of debt… […]
  • Loftware acquires Prisym ID
    Loftware announced that it acquired Prisym ID, a provider of regulated content and label management solutions. Prisym ID focuses on clinical trials, medical device and pharmaceutical labeling, with the acquisition set to expand Loftware’s enterprise labeling solution offerings for the medical device and pharmaceutical industries while enhancing Loftware’s end-to-end, cloud-based labeling platform with advanced clinical… […]
  • BD, Pfizer, Wellcome want to improve hospitals’ antimicrobial practices
    BD (NYSE:BDX) announced yesterday that it will collaborate with Pfizer (NYSE:PFE) and Wellcome to advance antimicrobial stewardship practices. The collaboration builds on ongoing efforts to advance the role of diagnostics in addressing the challenge of antimicrobial resistance (AMR), according to a news release. The companies will survey existing diagnostic practices to highlight benefits and gaps… […]
  • iRhythm CEO considers costs on the path to profitability
    Fresh off positive reimbursement news for its Zio remote external electrocardiogram monitoring device, the CEO of iRhythm Technologies (NSDQ:IRTC) doesn’t just have revenue on his mind. iRhythm President and CEO Quentin Blackford — the former Dexcom COO who replaced Mike Coyle in September — said his company will need to keep costs under control as it… […]

Leave a Reply